Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|July 28, 2022
Dr. Staehler on novel PET imaging agent for kidney cancer
Author(s)Urology Times staff
Advertisement
In this video, Michael Staehler, MD, a professor of Urology at the University of Munich, discusses early results with 68GA-EMP-100 PET, a novel agent for imaging c-MET expression in renal cell carcinoma. Staehler presented that abstract, “First in-human results of 68GA-EMP-100 PET for imaging c-MET expression in renal cell carcinoma,” at the 2022 AUA annual meeting (abstract
Advertisement
Related to this article
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to OpenFlo urinary catheter
2
FDA grants fast track designation to VIR-5500 for mCRPC
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
5